Pelican Cancer Foundation

Pelican Cancer Foundation

  • Facebook
  • Instagram
  • Twitter
  • YouTube
DONATE NOW
  • Home
  • About Us
    • What we do
      • Bowel cancer
      • Colorectal Liver Metastases
      • Prostate cancer
      • Bladder cancer
      • Pseudomyxoma peritonei
      • Our Research
      • Our achievements
      • Media
    • Who we are
      • Our board
      • Our team
      • Pelican Patrons
    • Our annual accounts
    • Pelican Cancer Foundation – What next?
    • Support Us
    • Job opportunities
    • Partners
  • Workshops
    • TIPTOP
      • Workshops
      • TIPTOP – Online resources
    • Pelican IMPACT
      • IMPACT – Completion & Evaluation
      • Workshops
      • IMPACT – Online resources
      • IMPACT – Partners and Sponsors
    • SPECC
      • SPECC – Completion & Evaluation
      • Workshops
      • SPECC – Online resources
      • SPECC – Partners and Sponsors
    • LOREC
    • What clinicians say about our courses
    • Faculty
    • Our sponsors
    • Become a sponsor
    • Request a course or topic
    • Give us feedback
    • Previous courses
  • Research
    • Research strategy
    • Bowel cancer research
      • POLARS
      • MERCURY 2 (Low Rectal Cancer Study)
      • Deferral of surgery study
      • TATME
      • IMPRESS
      • TRIGGER
      • Papers of interest
      • Timing of surgery
      • AMSOEC
      • MINSTREL
      • Completed research
        • Perineal wound healing registry
        • Beyond TME
        • Validation of the LARS score
        • MARVEL: Evaluation of EMVI positive rectal cancer
        • FLEX
        • TME Physical Simulation Model
        • Total Mesorectal Excision (TME)
        • MERCURY research programme
    • Peritoneal malignancy research
      • Colorectal Peritoneal Malignancy Database
      • Pseudomyxoma Pathology Atlas
    • Prostate Cancer Research
      • Focal therapy and HIFU research
      • MRI research for prostate cancer
      • Prostate cancer colloquiums
      • FORECAST
      • Trachtomap
      • Papers of interest
    • Liver cancer research
      • Completed research
        • EORTC studies
      • SERENADE
      • Papers of interest
    • Bladder cancer research
      • PELT
      • Papers of interest
    • Peer reviewers
    • Clinical trials
    • Information for researchers
      • Peer review process
      • Research review panel
      • Research Grant Application Guidance Notes
      • Terms and conditions of grants
      • Animals in medical research
      • Research costs
    • Surgical videos
  • For Patients
    • Patient stories
      • Bob’s story (prostate cancer)
      • Andrew’s story (prostate cancer)
      • Alan’s story (prostate cancer)
      • Raymond’s story (prostate cancer)
      • Anthony’s story (bowel cancer)
      • Elena’s story (bowel cancer)
      • Jay’s story (bladder cancer)
      • Terry’s story (liver cancer)
      • Derrick’s story (liver cancer)
      • Alex’s story (colorectal cancer)
      • Cheryll’s story (rectal cancer)
      • Eileen’s story
      • Richard’s story – irrigation
      • Tom’s story – complete response
      • Advanced metastatic bowel cancer
    • Bowel cancer
      • Our bowel cancer team
      • About bowel cancer treatment – TME
      • Low rectal cancer
      • Complete response to chemoradiotherapy in rectal cancer
      • Frequently asked questions about bowel cancer
      • Irrigation for colostomies
      • A patient’s advice
      • Symptom checker
      • Bowel cancer – useful contacts
    • Liver cancer
      • Our liver cancer team
      • About liver cancer treatment
      • Interventional radiology
      • Liver cancer – frequently asked questions
      • Carcinoid and neuroendocrine tumours
      • Liver cancer – want to read more?
    • Prostate cancer
      • Our prostate cancer team
      • Prostate cancer treatment options
      • Pelican’s position
    • Bladder cancer
      • Blue light cystoscopy
      • Bladder cancer – useful contacts
    • Pseudomyxoma peritonei
    • Kidney cancer
      • Our kidney cancer team
      • Kidney cancer – useful contacts
    • What is an MDT?
      • What an MRI reveals
      • Reporting cancer outcomes
    • Getting a second opinion
    • Clinical trials
      • Current clinical trials
    • Tell us your story
    • Still got questions about cancer?
    • Links
  • Support us
    • Make a donation
      • Make a donation
      • Why donate to Pelican?
      • Donate shares
      • Donate in memory
      • How your donations are spent
    • Fundraising
      • Our fundraisers
      • Fundraising ideas
      • Fundraising challenges
      • Fundraising resources
      • Our events
    • Leaving a Legacy
    • Volunteering Opportunities
    • Could you host a Pelican Talk?
    • Charity of the Year partnerships
    • Pelican Film Society
  • Online Shop
  • Events
  • Contact us

For Patients


  • Secondary liver cancer most often starts in the bowel.
    42% of patients with bowel cancer may go on to develop liver cancer.
    Surgery remains the only potential ‘cure’ for secondary liver cancer.
    Click to read more.

  • Kidney cancer is diagnosed in over 7 000 people in the UK each year.
    It is more common in men than in women, and becomes more common as people get older.
    Surgery is the main treatment for kidney cancer.
    Click to read more.

  • Bowel (colorectal) cancer is diagnosed in 38,000 people each year in the UK (1 in 18).
    With optimal treatment and surgery, more cures are possible with bowel cancer than all the other internal cancers.
    Click to read more.

  • Colon cancer is bowel cancer that is situated between the appendix and the rectum.
    Around 24 000 people are diagnosed in the UK each year.
    Click to read more.

  • Rectal cancer is bowel cancer that is situated in the lower part of the bowel.
    Around 14 000 people are diagnosed with rectal cancer in the UK each year, 4 700 of those with low rectal cancer.
    Click to read more.

  • Bladder cancer is diagnosed in between 10 000-12 000 people in the UK each year.
    Of these, around 4 000 people will die of the disease.
    Despite this, there are no dedicated bladder cancer charities.
    Click to read more.

  • Prostate cancer is the most common cancer in men in the UK
    ñ each year around 35,000 men are diagnosed with the disease.
    Although some prostate cancer is aggressive and can cause death,
    the majority of prostate cancers are unlikely to cause harm during a manís lifetime..
    Click to read more.

Pelican Cancer Foundation aims to save and improve lives by improving treatment, particularly surgery, for pelvic (bowel or colorectal, prostate and bladder) and liver cancers.

Though Pelican cannot provide any further information, advice or referral for patients directly (we do not have the expertise or resources within our charity offices to do so), we have gathered some information here that we hope may be helpful to patients and their families.

Under each type of cancer, the experienced consultants who make up the Pelican Cancer Foundation have answered some of the more frequently asked questions. Several patients have written about their experiences with cancer from diagnosis to treatment, and about their quality of life after treatment. You will also find a number of links to other relevant charities and organisations that may be able to provide direct patient support and with whom we regularly work.

Pelican Cancer FoundationFollow

Pelican Cancer Foundation
Pelican_CancerPelican Cancer Foundation@Pelican_Cancer·
5h

#BowelCancerAwarenessMonth #PelicanCancerFoundation

Reply on Twitter 1382936796049272833Retweet on Twitter 13829367960492728331Like on Twitter 13829367960492728331Twitter 1382936796049272833
Pelican_CancerPelican Cancer Foundation@Pelican_Cancer·
15 Apr

#BowelCancerAwarenessMonth #PelicanCancerFoundation

Reply on Twitter 1382574408661864450Retweet on Twitter 13825744086618644503Like on Twitter 13825744086618644502Twitter 1382574408661864450
Pelican_CancerPelican Cancer Foundation@Pelican_Cancer·
14 Apr

#BowelCancerAwarenessMonth #PelicanCancerFoundation

Reply on Twitter 1382212019726680067Retweet on Twitter 13822120197266800671Like on Twitter 13822120197266800671Twitter 1382212019726680067
Load More...

To view our privacy policy - click here.
Registered charity no: 1141911

Copyright © 2021 · Outreach Pro Theme on Genesis Framework · WordPress · Log in